Report Overview
Pharmacogenomics (PGx) is a branch of precision medicine that studies how an individual’s genetic makeup affects their response to drugs. It combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to tailor drug treatments for individual patients, improving efficacy and reducing adverse effects. By analyzing genetic variations, pharmacogenomics helps in developing personalized treatment plans, minimizing trial-and-error prescriptions, and optimizing drug dosages.
Market Analysis
The global Pharmacogenomics (PGx) Market is projected to grow from US$ 8,569.5 million in 2024 to US$ 14,590 million by 2030
Reflecting a CAGR of 9.3% during the forecast period.
Regional Analysis
North America
Europe
Asia-Pacific
South America
Middle East & Africa
Competitor Analysis
Haitian International
ENGEL Holding GmbH
ARBURG GmbH
Sumitomo Heavy Industries
Milacron
Market Segmentation
By Application:
Cardiovascular Diseases (CVD
Central Nervous System (CNS) Disorders
Cancer/Oncology
Infectious Diseases
Other
By Type:
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Other
